Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 158 Jul 28 – Oct 25, 2026
- Disclosed funding
- $6B 122 disclosed amounts
- Median round
- $24M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| PT Pixelgen TechnologiesCompany profile High-throughput platform mapping molecular cell architecture at nanoscale resolution High-throughput platform mapping molecular cell architecture at nanoscale resolution | $15.5M | Series B | Biotech | Sweden | Investors | |
| KI KaliVir ImmunotherapeuticsCompany profile Develops oncolytic immunotherapies for patients with advanced solid tumors Develops oncolytic immunotherapies for patients with advanced solid tumors | $14M | Series A | Biotech | United States | Investors | |
| NB Network BioCompany profile Builds AI models trained on patient tissue and clinical data for disease diagnostics Builds AI models trained on patient tissue and clinical data for disease diagnostics | $50M | StrategicUndisclosed | Biotech | United States | Investors | |
| A AuraGxPCompany profile AI-native SaaS platform connecting quality, procurement and vendor management for life sciences AI-native SaaS platform connecting quality, procurement and vendor management for life sciences | Undisclosed | Seed | Biotech | United States | Investors Undisclosed | |
| C ComputomicsCompany profile Machine learning platform predicting crop variety performance for climate-smart breeding Machine learning platform predicting crop variety performance for climate-smart breeding | €6.3M | Series B | Biotech, Agritech | Germany | Investors | |
 AbcuroCompany profile Clinical-stage immunotherapies targeting pathogenic cytotoxic T cells in autoimmune disease. Clinical-stage immunotherapies targeting pathogenic cytotoxic T cells in autoimmune disease. | $66M | Series DSeries C+ | Biotech | United States | Investors | |
| LT Develops neuro-metabolic therapeutics for schizophrenia and ALS | $30M | Series A | Biotech | United States | Investors | |
| G GamgeeCompany profile Gamgee develops personalized mRNA vaccines for dogs with cancer, designed from the genetic profile of each dog’s tumor. Gamgee develops personalized mRNA vaccines for dogs with cancer, designed from the genetic profile of each dog’s tumor. | $4M | Seed | Biotech | United States | Investors | |
| eH eubiOmic HealthCompany profile eubiOmic Health develops clinical nutrition for patients with a temporary ileostomy following rectal surgery. eubiOmic Health develops clinical nutrition for patients with a temporary ileostomy following rectal surgery. | €200K | First investment roundUndisclosed | Biotech | Spain | Investors | |
| R RasynCompany profile Rasyn gives chemists a chat interface to run real chemistry software tools on their own hardware. Rasyn gives chemists a chat interface to run real chemistry software tools on their own hardware. | Undisclosed | Seed | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jul 28, 2026
- 1Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
10rounds0led - 2RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
9rounds3led - 3Y Combinator (YC)
Molagri, Sensible Biotechnologies, WonderTx
6rounds0led - 4Catalio Capital Management
BigHat Biosciences, Basecamp Research, Enveda
6rounds2led - 5Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
5rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.